Oncology · Gastrointestinal Stromal TumorTrial Updateclinicalmid-term

Study on Genetic Aberrations in Wild Type GIST Patients in Taiwan

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/3/2026, 6:03:24 AM

Assessment confidence: 52% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

This study is significant as it addresses a critical gap in understanding the genetic landscape of wild type GIST, which could lead to the identification of new therapeutic targets. The findings may influence future treatment strategies and the development of targeted therapies in oncology. Regulatory context from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) supports the near-term read. Assessment grounded in 7 ranked evidence items (2 high-relevance).

Strategic Assessment

Insights from this study could inform future therapeutic strategies and development of targeted therapies for wild type GIST patients. The strongest clinical anchor is Oncogenetic Panel and Integrated Clinical Data Registry Study for Wild Type Gastrointestinal Stromal Tumor Patients (ClinicalTrials.gov), sub-indication match (ild). In ild, 5 regulatory and 0 competitive items passed relevance filtering for Imatinib.

Competitive Pressure

The most relevant competitive pressure comes from This study addresses a gap in understanding the genetic landscape of wild type GIST, potentially identifying new treatment targets..

Regulatory Outlook

Regulatory risk is concentrated around Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA). Sub-indication match (ild). The outcomes of this study may inform regulatory pathways for new treatments targeting genetic aberrations in wild type GIST, influencing approval processes for future therapies.

Key Risks

Elevated medium regulatory exposure for Imatinib could delay market entry or constrain labeling if agency review intensifies.
Regulatory risk from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) could weigh on Imatinib through agency review timelines and labeling constraints if follow-through weakens.

Key Opportunities

If successful, the insights from this study could lead to the development of new therapies for wild type GIST, potentially impacting market share for existing treatments like Imatinib and Sunitinib.
Upside for Imatinib may improve if Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA) delivers favorable follow-through.
Insights from this study could inform future therapeutic strategies and development of targeted therapies for wild type GIST patients.

What Would Change This Assessment

This becomes more urgent if Monitor results from the oncopanel tests and any subsequent treatment developments based on genetic findings.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
Outcome from Oncogenetic Panel and Integrated Clinical Data Registry Study for Wild Type Gastrointestinal Stromal Tumor Patients would change the regulatory/clinical read.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026
FDAhigh relevance
Sub-indication match (ild)
FDA document
View source
FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes
FDAmedium relevance
Regulatory pathway relevance (approval)
FDA document
View source
FDA Alerts Health Care Providers to Cases of Neurologic Complications from General Anesthesia Linked to Genetic Variant in Patients of Maternal Venezuelan Ancestry
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — ONTRUZANT (SUPPL)
FDAmedium relevance
Regulatory pathway relevance (bla)
FDA document
View source
FDA AP — INQOVI (SUPPL)
FDAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Opportunities for patients and the public to be involved in the work of the MHRA
MHRAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA Approves Drug for Pediatric Stage 3 Type I Diabetes
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Oncogenetic Panel and Integrated Clinical Data Registry Study for Wild Type Gastrointestinal Stromal Tumor Patients
ClinicalTrials.govhigh relevance
Sub-indication match (ild)
FDA document
View source
Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).
ClinicalTrials.govmedium relevance
Sub-indication match (ild)
FDA document
View source
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
ClinicalTrials.govlow relevance
Sponsor/company relevance (Lilly)
FDA document
View source
A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as Single Agent and in Combination in Patients With Advanced Solid Tumors
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Cabozantinib plus Nivolumab Shows Promise in Advanced Non-Clear Cell RCC
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Type 2 diabetes remission in gynaecologic oncology patients completing an acute preoperative weight loss protocol: a case series.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Intratumor Lactobacillus drives ferroptosis resistance via D-lactate-STAT3 K631 lactylation in esophageal squamous cell carcinoma.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Transdermal versus oral hormone replacement therapy and bone mass density in Turner syndrome patients: a pilot study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Imatinib
Sunitinib

Commercial impact

medium

If successful, the insights from this study could lead to the development of new therapies for wild type GIST, potentially impacting market share for existing treatments like Imatinib and Sunitinib.

Regulatory impact

medium

The outcomes of this study may inform regulatory pathways for new treatments targeting genetic aberrations in wild type GIST, influencing approval processes for future therapies.

What to watch

Monitor results from the oncopanel tests and any subsequent treatment developments based on genetic findings.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.